BioCentury | Feb 5, 2019
Distillery Therapeutics

Cancer

INDICATION: Liver cancer Patient sample and cell culture studies suggest inhibiting USP7 or its downstream mediator YAP1 could help treat hepatocellular carcinoma (HCC). In patient samples, tumor levels of USP7 and YAP1 proteins were higher...
BioCentury | Nov 2, 2017
Targets & Mechanisms

Golden State of DUBs

Four papers in the last two weeks describing inhibitors of the ubiquitin-regulating protein USP7 could signal an important breakthrough in the ability to drug DUBs, a class of enzymes that has been stubbornly intractable until...
BioCentury | Sep 19, 2016
Clinical News

Inecalcitol: Phase II started

Hybrigenics began a double-blind, placebo-controlled, international Phase II trial to evaluate 4 mg oral inecalcitol once daily plus IV decitabine in 110 patients ages >=65 who are unfit for standard chemotherapy. Hybrigenics has exclusive, worldwide...
BioCentury | Jul 13, 2015
Finance

Tiers, some fears

3Q15 Financial Markets Preview With biotech more than six years into a bull run, most of the sector's bankers and buysiders remain comfortable in uncharted waters because generalists are not jumping ship en masse in...
BioCentury | Jun 8, 2015
Company News

PicoSeq, Hybrigenics, Ecole Normale Superieure, Bpifrance deal

The entities partnered to develop PicoSeq’s SIMDEQ single-molecule magnetic detection and quantification technology for detecting epigenetic signals from DNA. The project, called EPIGENETIX2, was selected for funding in the second phase of the French Worldwide...
BioCentury | Feb 2, 2015
Company News

Hybrigenics, Servier deal

Hybrigenics extended by one year its 2011 deal with Servier to identify compounds against deubiquitinating enzyme targets. Hybrigenics received €920,000 ($1 million) for the extension (see BioCentury, Oct. 17, 2011 & Feb. 3, 2014). Hybrigenics...
BioCentury | Nov 3, 2014
Financial News

Hybrigenics completes private placement

Hybrigenics S.A. (Euronext:ALHYG), Paris, France Business: Cancer, Proteomics, Supply/Service Date completed: 2014-10-22 Type: Private placement Raised: EUR4.6 million ($5.9 million) Shares: 3.5 million Price: EUR1.32 Shares after offering: 29.4 million Investor: Crede Capital Group WIR...
BioCentury | Oct 9, 2014
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Pancreatic cancer Vitamin D receptor (VDR) In vitro and mouse studies suggest vitamin D analogs could help treat pancreatic cancer. VDR levels were higher in...
BioCentury | May 26, 2014
Clinical News

Inecalcitol regulatory update

FDA granted Orphan Drug designation to inecalcitol from Hybrigenics to treat chronic lymphocytic leukemia (CLL). The oral synthetic analog of vitamin D is in Phase II testing for CLL and completed a Phase IIa trial...
BioCentury | Apr 7, 2014
Financial News

Hybrigenics completes private placement

Hybrigenics S.A. (Euronext: ALHYG), Paris, France Business: Cancer, Proteomics, Supply/Service Date completed: 3/26/14 Type: Private placement Raised: €3.8 million ($5.2 million) Shares: 1.6 million Price: €2.35 Shares after offering: 25 million Investors: Pradeyrol Developpement; existing...
Items per page:
1 - 10 of 128
BioCentury | Feb 5, 2019
Distillery Therapeutics

Cancer

INDICATION: Liver cancer Patient sample and cell culture studies suggest inhibiting USP7 or its downstream mediator YAP1 could help treat hepatocellular carcinoma (HCC). In patient samples, tumor levels of USP7 and YAP1 proteins were higher...
BioCentury | Nov 2, 2017
Targets & Mechanisms

Golden State of DUBs

Four papers in the last two weeks describing inhibitors of the ubiquitin-regulating protein USP7 could signal an important breakthrough in the ability to drug DUBs, a class of enzymes that has been stubbornly intractable until...
BioCentury | Sep 19, 2016
Clinical News

Inecalcitol: Phase II started

Hybrigenics began a double-blind, placebo-controlled, international Phase II trial to evaluate 4 mg oral inecalcitol once daily plus IV decitabine in 110 patients ages >=65 who are unfit for standard chemotherapy. Hybrigenics has exclusive, worldwide...
BioCentury | Jul 13, 2015
Finance

Tiers, some fears

3Q15 Financial Markets Preview With biotech more than six years into a bull run, most of the sector's bankers and buysiders remain comfortable in uncharted waters because generalists are not jumping ship en masse in...
BioCentury | Jun 8, 2015
Company News

PicoSeq, Hybrigenics, Ecole Normale Superieure, Bpifrance deal

The entities partnered to develop PicoSeq’s SIMDEQ single-molecule magnetic detection and quantification technology for detecting epigenetic signals from DNA. The project, called EPIGENETIX2, was selected for funding in the second phase of the French Worldwide...
BioCentury | Feb 2, 2015
Company News

Hybrigenics, Servier deal

Hybrigenics extended by one year its 2011 deal with Servier to identify compounds against deubiquitinating enzyme targets. Hybrigenics received €920,000 ($1 million) for the extension (see BioCentury, Oct. 17, 2011 & Feb. 3, 2014). Hybrigenics...
BioCentury | Nov 3, 2014
Financial News

Hybrigenics completes private placement

Hybrigenics S.A. (Euronext:ALHYG), Paris, France Business: Cancer, Proteomics, Supply/Service Date completed: 2014-10-22 Type: Private placement Raised: EUR4.6 million ($5.9 million) Shares: 3.5 million Price: EUR1.32 Shares after offering: 29.4 million Investor: Crede Capital Group WIR...
BioCentury | Oct 9, 2014
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Pancreatic cancer Vitamin D receptor (VDR) In vitro and mouse studies suggest vitamin D analogs could help treat pancreatic cancer. VDR levels were higher in...
BioCentury | May 26, 2014
Clinical News

Inecalcitol regulatory update

FDA granted Orphan Drug designation to inecalcitol from Hybrigenics to treat chronic lymphocytic leukemia (CLL). The oral synthetic analog of vitamin D is in Phase II testing for CLL and completed a Phase IIa trial...
BioCentury | Apr 7, 2014
Financial News

Hybrigenics completes private placement

Hybrigenics S.A. (Euronext: ALHYG), Paris, France Business: Cancer, Proteomics, Supply/Service Date completed: 3/26/14 Type: Private placement Raised: €3.8 million ($5.2 million) Shares: 1.6 million Price: €2.35 Shares after offering: 25 million Investors: Pradeyrol Developpement; existing...
Items per page:
1 - 10 of 128